Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial

NCT06485544 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

DRUG: Adebrelimab + Etoposide + Platinum-based Therapy
DRUG: Etoposide + Platinum-based Therapy

Sponsor

Tang-Du Hospital